ARKG Holdings of Repare Therapeutics (RPTX) - Updated Daily
Join Premium Plan
Key Statistics
Statistics
Clinical Trials (5)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $14.34 |
| ⚖️Weighting | 🧢Market Cap |
| 1.12% | $600.45m |
| 🏋🏿♂️Weight Rank In ARKG | 🧮Price to Sales |
| 31 | 79.01 |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 75 | 🇨🇦Canada |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
| $31.49 | 6.83% |
| Description | |
|---|---|
| Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Polθ inhibitor program. | |
| Website | |
| reparerx.com |
Research Notes and Commentary for RPTX
October 8, 2021
October 7-8: ARK Trades and Storylines
Trading Floor